Journal Home
Search for

Volume 20, Issue 3, Pages 198-203 (March 2010)


View previous. 9 of 28 View next.

Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion

Nicole LeskoaCorresponding Author Informationemail address, Karin Naessab, Rolf Wiboma, Nicola Solarolia, Inger Nennesmoa, Ulrika von Döbelna, Anna Karlssona, Nils-Göran Larssonac

Received 12 August 2009; received in revised form 9 November 2009; accepted 25 November 2009.

Abstract 

Deficiency of thymidine kinase-2 (TK2) has been described in children with early onset fatal skeletal myopathy. TK2 is a mitochondrial deoxyribonucleoside kinase required for the phosphorylation of deoxycytidine and deoxythymidine and hence is vital for the maintenance of a balanced mitochondrial dNTP pool in post-mitotic tissues. We describe a patient with two novel TK2 mutations, which caused disease onset shortly after birth and death at the age of three months. One mutation (219insCG) generated an early stop codon, thus preventing the synthesis of a functional protein. The second mutation (R130W) resulted in an amino acid substitution, which caused a severe reduction (<3%) of TK2 enzyme activity. These two novel TK2 mutations cause an extremely severe phenotype with overwhelming central nervous system symptoms not commonly seen in patients with TK2-deficiency. We conclude that the severe clinical presentation in this patient was due to a virtual lack of mitochondrial TK2 activity.

a Department of Laboratory Medicine, Division of Metabolic Diseases, Karolinska Institutet, 141 86 Stockholm, Sweden

b Department of Clinical Sciences, Karolinska Institutet, 141 86 Stockholm, Sweden

c Max Planck Institute for Biology of Ageing, Gleueler Strasse 50a, D-50931 Cologne, Germany

Corresponding Author InformationCorresponding author. Tel.: +46 8 5858 2784; fax: +46 8 5858 2760.

PII: S0960-8966(09)00697-X

doi:10.1016/j.nmd.2009.11.013


View previous. 9 of 28 View next.